PLK1 and cancer: The diverse effect of PLK1 inhibition in cancer therapy motivates us to identify the downstream effector as an attractive target.[15, 16] Using genome‐wide expression profiling analysis, we showed that PLK1 inhibition suppressed a cluster of cell cycle‐related genes that were upregulated by oxaliplatin treatment.